Mu Wang

Profile



Prof. Wang earned his PhD in Bio-Organic Chemistry from Washington University in St. Louis, Missouri, USA, and was an NIH/NRSA postdoctoral fellow studying mechanisms of DNA repair in mammalian system. Before joining XJTLU, he was a tenured Associate Professor of Biochemistry and Molecular Biology at the Indiana University School of Medicine (IUSM), USA. He joined the faculty of Indiana University School of Medicine in 2001 as the Scientific Director of a newly established Proteomics Core. In 2004, he spearheaded a biotech CRO, Monarch Life Sciences, and served as its VP of Research until 2010. He also served as the director of Proteomics Core Lab from 2001 to 2016 at IUSM. His research centers around biomarkers and drug target discovery, and deciphering the protein interaction networks in complex human diseases such as cancer with the use of high throughput proteomics technologies such as quantitative mass spectrometry platforms. Additionally, he also has expertise in mammalian DNA repair and macro-molecular interaction studies using surface plasmon resonance (SPR) analysis. He has collaborated with more than 100 basic and clinical investigators both across the United States and internationally to advance knowledge related to human health. He has supervised >40 graduate students, postdoctoral fellows, and research associates. He was also a Co-Principal Investigator on the U.S. National Cancer Institute’s Clinical Proteomics Technologies Application for Cancer (CPTAC) Program. He received a number of awards including a Young Investigator’s Award in 2004 HUPO meeting. He has published close to 100 peer-reviewed articles in DNA repair, biochemistry, and proteomics related journals and book chapters, and served as an expert reviewer for many high-impact journals as well as NIH and the U.S. Department of Defense grant applications.


  • Qualifications

    • Ph.D., Bio-organic Chemistry, Washington University, St. Louis, Missouri, USA – 1998
    • M.S., Organic Chemistry, Oregon State University, Corvallis, Oregon, USA – 1993
    • B.S., Chemistry, Sichuan University, Chengdu, Sichuan, China – 1986
  • Experience

    • Tenured Associate Professor, Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA – 2010-2018
    • Tenure-track Assistant Professor, Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA – 2004-2010
    • Assistant Scientist, Assistant Professor (part-time), Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA – 2001-2004
    • Director of Proteomics, Indiana University School of Medicine, Indianapolis, Indiana, USA – 2001-2016
    • Vice President of Research & Development, Monarch Life Sciences, Indianapolis, Indiana, USA – 2004-2010
    • NIH/NSRA Postdoctoral Fellow, Indiana University School of Medicine, Indianapolis, Indiana, USA – 1998-2001
  • Research interests

    • Pathogenesis of Parkinson's Disease
    • Molecular Mechanisms of Drug Resistance in Cancer and Biomarker Development for Cisplatin Resistance in Human Ovarian Cancer
    • Targeting Alterred Pyruvate Metabolism for Prostate Cancer Therapy
    • Development of New Strategies/Methodologies in Proteomics/Metabolomics and Their Applications in Biomedical Research
    • Biomarker Clinical Applications
  • Articles

    • Suvannasankha, A; Crean, C. D; Leyes, H. M; Wongsaengsak, S; Qi, G; Kim, J; Wang, M. (2018) Proteomic characterization of plasma cells from patients with multiple myeloma. J Proteomics Bioinform, 11, 008-016.
    • Culleton, S. P; Kanginakudru, S; DeSmet, M. L; Gilson, T; Xie, F; Wu, S-Y; Chiang, C-M; Qi, G; Wang, M; Androphy, E. J. (2017) Phosphorylation of the bovine papillomavirus E2 protein on tyrosine regulates its transcription and replication functions. J Virol, 91, e01854-16.
    • Lai, X; Wang, M; McElyea, S. D; Sherman, S; House, M; Korc, M. (2017) A microRNA signature in circulating exosomes is superior to exosomal glypican-1 for diagnosing pancreatic cancer. Cancer Lett, 393, 86-93.
    • Zhao, H; Pflug, B. R; Lai, X; Wang, M. (2016) Metabolic and Molecular Regulation of Dietary Polyunsaturated Fatty Acids on Prostate Cancer. Proteomics – Clinical Applications, 10, 267-279.
    • Zhao, H; Pflug, B. R; Lai, X; Wang, M. (2016) Pyruvate dehydrogenase alpha 1 as a target of omega-3 polyunsaturated fatty acids in human prostate cancer through a global phosphoproteomic analysis. Proteomics, 16, 2419-2431.
    • Lai, X; Kline, J. A; Wang, M. (2015) Development, Validation, and Comparison of Four Methods to Simultaneously Quantify L-Arginine, Citrulline, and Ornithine in Human Plasma Using Hydrophilic Interaction Liquid Chromatography and Electrospray Tandem Mass Spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 1005, 47-55.
    • Gaji, R. Y; Johnson, D. E; Wang, M; Hudmon, A; Arrizabalaga, G. (2015) Phosphorylation of a myosin motor by TgCDPK3 facilitates rapid initiation of motility during Toxoplasma egress. PLOS Pathogens, 11(11), e1005268, 1-20.
    • Wang, M.; Brown, D. G. P.; You, J.; Bemis, K. (2014) Putative Surrogate Biomarkers to Predict Patients with Acquired Platinum Resistance in Ovarian Cancer. Journal of Molecular Biomarkers & Diagnosis, 5(4), 184.
    • Liao, J.; Wu, C.; Burlak, C.; Zhang, S.; Sahm, H.; Wang, M.; Zhang, Z-Y.; Vogel, K. W.; Riddle, S.; Federici, M.; Nichols, J.; Liu, D.; Cookson, M. R.; Stone, T. A.; and Hoang, Q. Q. (2014) The Parkinson's disease-associated mutation R1441H in LRRK2 prolongs the 'active-state' of its GTPase domain. Proc Natl Aca Sci USA, 111(11), 4055-4060.
    • Abbatiello, S. E.; Mani, D. R.; Schilling, B.; MacLean, B.; Zimmerman, L. J.; Feng, X.; Cusack, M. P.; Sedransk, N.; Hall, S. C.; Addona, T.; Allen, S.; Dodder, N. C.; Ghosh, M.; Held, J. M.; Hedrick, V.; Inerowicz, H. D.; Jackson, A.; Keshishian, H.; Kim, J. W.; Lyssand, J. S.; Riley, C. P.; Rudnick, P.; Sadowski, P.; Shaddox, K.; Smith, D.; Tomazela, D.; Wahlander, A.; Waldemarson, S.; Whitwell, C. A.; You, J.; Zhang, S.; Kinsinger, C. R.; Mesri, M.; Rodriguez, H.; Borchers, C. H.; Buck, C.; Fisher, S. J.; Gibson, B. W.; Liebler, D.; MacCoss, M.; Neubert, T. A.; Paulovich, A.; Regnier, F.; Skates, S. J.; Tempst, P.; Wang, M.; Carr, S. A. (2013) Design, Implementation, and Multi-Site Evaluation of a System Suitability Protocol for the Quantitative Assessment of Instrument Performance in LC-MRM-MS. Mol Cell Proteomics, 12(9), 2623-2639.
    • Langley, R. J; Tsalik, E. L.; van Velkinburgh, J. C.; Glickman, S. W.; Rice, B. J.; Wang, C.; Chen, B.; Carin, L.; Suarez, A.; Mohney, R. P.; Freeman, D. H.; Wang, M.; You, J.; Wulff, J.; Thompson, J. W.; Moseley, M. A.; Reisinger, S.; Edmonds, B. T.; Grinnell, B.; Nelson, D. R.; Dinwiddie, D. L; Miller, N. A.; Saunders, C. J.; Soden, S. S.; Rogers, A. J.; Gazourian, L.; Fredenburgh, L. E.; Massaro, A. F.; Baron, R. M.; Choi, A. M. K.; Corey, G. R.; Ginsburg, G. S.; Cairns, C. B.; Otero, R. M.; Fowler, V. G. Jr; Rivers, E. P.; Woods, C. W.; Kingsmore, S. F. (2013) An Integrated Clinico-metabolomic Model Improves Prediction of Death in Sepsis. Science – Translational Medicine, 5(195), 195ra95.
    • Zieger, M. A; Gupta, M. P; Wang, M. (2011) Proteomic analysis of endothelial cold-adaptation. BMC Genomics, 12, 630.
  • Proceedings

    • Chen, J. Y.; Pinkerton, S. L.; Shen, C.; and Wang, M. (2006) An Integrated Computational Proteomics Method to Extract Protein Targets for Fanconi Anemia Studies. Proceedings of the 21st Annual ACM Symposium on Applied Computing, Dijion, France, 1, 173-179.
    • Chen, J. Y.; Shen, C.; Yan, Z.; Brown, D. P.; Wang, M. (2006) A systems biology case study of ovarian cancer drug resistance. Comput Syst Bioinformatics Conf, 389-398.
  • Books, monographs, compilations and manuals

    • Mu Wang & Frank A. Witzmann. (2016), Eds., Role of Biomarkers in Medicine, InTech, Rijeka, Croatia.
  • Chapters, cases, readings and supplements

    • Mu Wang & Jinsam You. (2012) Mass Spectrometry for Protein Quantification in Biomarker Discovery. In: Methods in Molecular Biology – Functional Genomics Methods and Protocols, 815: Chapter 16, pp. 199-225, edited by Michael Kaufmann & Claudia Klinger, Humana Press Inc., Totowa, NJ, USA
    • Mu Wang & Frank A. Witzmann. (2012) Proteomics in Drug Discovery and Development. In: Encyclopedia of Drug Metabolism and Interactions, Vol. IV, Part VII: Role of Metabolism in Toxicology and Pharmacology, L. Wienkers and P. Korytko, Eds., John Wiley and Sons, Inc., Hoboken, NJ, 1-34.
    • Mu Wang. (2011) Chapter 8 - DNA repair, cancer and cancer therapy. In: DNA Repair and Human Health, edited by Sonya Vengrova, InTech, Rijeka, Croatia, ISBN 978-953-307-612-6, 239-278.
    • Mu Wang, Jin-sam You, Kerry G. Bemis, Dawn P. G. Fitzpatrick. (2008) Label-free mass spectrometry-based protein quantification technologies in protein biomarker discovery. In: Biomarker Methods in Drug Discovery and Development, Humana Press Inc., Totowa, NJ, 211-230.
    • Witzmann, F.A. & Wang, M. (2005) Proteomics. In: Pharmacogenomics, Kalow, W., 2nd ed., Marcel Dekker, Inc., New York, NY, pp. 413-440.
  • Conference presentations

    • Keynote Speaker, The 3rd Global Summit and Expo on Proteomics, Amsterdam, Netherlands, November 18-19, 2019, title: “LC/MS-based Assays for Clinical Applications”.
    • The 12th Annual World Cancer Congress, Osaka, Japan, May 15-17, 2019, Session Chair, title: “Proteomic Characterization of Plasma Cells from Patients with Multiple Myeloma”.
    • The 2nd Global Summit and Expo on Proteomics, Dallas, USA, November 19-20, 2018, title: “Prostate Cancer Drug Target Identification Through Global Expression Proteomics and Phosphoproteomics Studies”.
    • The 16th Annual Congress of International Drug Discovery Science and Technology, Jinan, China, November 6-8, 2018, title: “Is Pyruvate Dehydrogenase Complex a Legitimate Drug Target for Prostate Cancer?”
    • International Conference on Biomarker Research in Clinical Medicine, Paris, France, February 20, 2018, title: “The Effects of Dietary Polyunsaturated Fatty Acids on Prostate Cancer: Unbiased Proteomic and Phosphoproteomic Studies”.
    • International Summit on Current Trends in Mass Spectrometry, New Orleans, LA, July 13-15, 2015, title: “The Effects of Dietary Unsaturated Fatty Acids on Prostate Cancer – A Proteomic Approach”.
    • Session Chair and Speaker, 4th International Conference on Drug Discovery & Therapy, Dubai, United Arab Emirates, February 12-15, 2012, title: “Superoxide Dismutase 1 as a Target for Chemosensitization of Platinum Resistant Ovarian Cancer Cells”.
    • International Conference & Exhibition on Cancer Science & Therapy, Las Vegas, NV, August 15-17, 2011, title: “Targeting Superoxide Dismutase 1 for Chemosensitization of Platinum Resistant Ovarian Cancer Cells”.
    • The 2nd World Cancer Congress, Beijing, China, June 22-25, 2009, title: “Discovery and Validation of Biomarkers of Cisplatin Resistance in Human Ovarian Cancer Using Proteomics Approaches”.
    • Session Chair and Speaker, 2009 BIT Life Sciences Annual Protein/Peptide Conference (PepCon 2009), Seoul, South Korea, April 2-5, 2009, title: “Targeted Assay Development Using Mass Spectrometry”.
    • Molecular Medicine Tri-Conference, San Francisco, CA, February 26, 2009, title: “Cisplatin Resistance Biomarker Development”.
    • Keynote Speaker, 2008 BIT Life Sciences Annual Protein/Peptide Conference (PepCon 2008), Shenzhen, China, April 22-24, 2008, title: “Discovery and Validation of Biomarkers of Cisplatin Resistance in Human Ovarian Cancer Using Proteomics Approaches”.
    • 2007 Biomarker Discovery Summit, Philadelphia, PA, September 17-19, 2007, title: “Searching for Potential Biomarkers of Cisplatin Resistance in Human Ovarian Cancer”.
    • NIH/NCI, Bethesda, MD, February 23, 2007, title: “Discovery of Cisplatin Resistance Biomarkers in Ovarian Cancer using Quantitative Mass Spectrometry”.
    • SBIR ASSETs Meeting, Boston, MA, December 6-8, 2006, title: “Biomarker Discovery using Proteomics”.
    • Applied Biosystems Seminar Series, Bethesda, MD, December 7, 2006, title: “Absolute Quantification of an ADH Isoform Enzyme in Human Liver Using the Multiple-Reaction-Monitoring Approach”.
    • American Cancer Society - Great Lakes Cancer Symposium, University of Michigan, Ann Arbor, MI, September 19, 2003, title: “Functional Analysis of Xeroderma Pigmentosum Complementing Group C (XPC) in DNA Damage Recognition of Nucleotide Excision Repair”.
  • Grants

    • NIH/NIGMS (R01 GM071714), Co-Investigator (2006-2011)
    • NIH/NIAID (U01AI066569), Co-PI (2007-2008)
    • Biomedical Research Grant, Indiana University, PI (2002-2004)
    • NIH/NHLBI (R01 HL055716), Co-Investigator (2006-2011)
    • NIH/NIAMS (AR68332), Co-Investigator (2015-2017)
    • NIH/NIDDK (P01DK056788), Co-Investigator (2017-2018)
    • NIH/NIAID (R01 AI10762), Co-Investigator (2016-2018)
    • Department of Defense (W81XWH-08-1-0694), Co-PI (2011-2013)
    • Multiple Myeloma Research Foundation, PI (2008-2011)
    • Ataxia-Telangiectasia (A-T) Children’s Project, PI (2007-2008)
    • NIH/NCI CPTAC Consortium Grant, Co-PI (2006-2011)
    • W.M. Keck Foundation Research Fund, Co-Investigator (2006-2009)
    • Showalter Research Trust Fund, PI (2002-2004)
    • Indiana 21st Century Research and Technology Fund, Co-PI (2004-2006)
    • NIH/NIAID (1U01AI066569-01), Co-PI (2007-2008)
  • Professional service activities

    • Editorial Board Member (2017-), Annals of Cancer Research and Therapeutics
    • Editorial Board Member (2015-), Journal of Medical Genomics & Biomarkers
    • Editorial Board Member (2010-), Journal of Carcinogenesis & Mutagenesis
    • Editorial Board Member (2009-), Journal of Pediatric Biochemistry
    • Guest Editor (2005), Briefings in Functional Genomics and Proteomics – Special Issue: Proteomics Tools - Advances and Applications
    • Swiss National Science Foundation (SNSF), Reviewer (2018)
    • NIH Study Section – ZRG1 PSE-P 03 M NIA Special Emphasis Panel (2017)
    • NIH Study Section - ZCA1 SRB-8 (M1) NCI Omnibus R03 & R21 SEP-9 (2016)
    • The India Alliance – Fellowship for senior investigators, Reviewer (2016)
    • Department of Defense Army Research Office, Reviewer (2012)
    • NIH Study Section – ZRG1 IMST-C30 (S10 applications) (2009)
    • NIH Study Section – The Integrative Cancer Biology Program (ICBP): Centers for Cancer Systems Biology (CCSB) (2009)
    • The Ontario Research Fund – Global Leadership Round in Genomics & Life Sciences Competition, Reviewer (2009)
  • Teaching activities

    • BIO312 Protein Structure and Function
    • BIO108 Organic Chemistry for Biologists
    • BIO401 Research Methods in Biotechnology
  • Professional memberships

    • American Society for Mass Spectrometry (ASMS)
    • American Association for Cancer Research (AACR)
    • International Human Proteome Organization (HUPO)
  • Awards and honours

    • Guest on “Sound Medicine” radio interview, USA, 2007
    • Guest on the journal “Proteomics” webcast – Cisplatin resistance of ovarian cancer, 2006
    • Interview Guest on World Talk Radio (San Francisco) – Science & Society, USA
    • Young Investigator Award, International Human Proteome Organization, 2004
    • Invited Guest Speaker, American Broadcasting Company (ABC)’s Webcast on "Proteomics as a new tool for biomedical sciences", USA
    • Individual National Research Service Award (F32), National Institutes of Health (NIH), USA
  • 电话

    +86 (0)512 88184673
  • 电子邮件

    Mu.Wang@xjtlu.edu.cn
  • 地址

    P236, Public Building 2nd Floor
    XJTLU Wisdom Lake Academy of Pharmacy

    Xi'an Jiaotong-Liverpool University
    Suzhou Dushu Lake Science and Education Innovation District
    Suzhou Industrial Park
    Suzhou
    P.R.China
    215123